thank the On Thank our call Martin then the for and will everyone you, Sarah. remainder we results. Good will for you review afternoon and outline of update today’s milestones on year Sam joining financial clinical key you programs, us.
we the your to always, As look answering at questions close forward the of call.
will currently in company sponsored start our negative ADC in cancer We studies both with glembatumumab first metastatic and lead vedotin, breast melanoma. triple the
completed enrolment negative August disclosed, As in cancer was on XXXX study. triple breast previously in METRIC in XXX patients study with
this inherent orphan population, in especially enriched the significant an recruiting patient indication, challenges a Given accomplishment. within an achieving milestone was
any or the screened point end were The consistent assessed the to study of we on be XX% XX% progression will of for XXX events is point the patient with earlier where study none that and screening which randomizations see we reaching of therapies from disease XXX associated the disease. target an across Canada or the We to the and independent analysis with few Approximately to indication EU, cause. more sites studies outcomes In total, end glemba We that The is offer METRIC patients, are threshold. primary to based primary are and greater scans. the our are a who will participated defined of potentially progression central time free families METRIC givers that new in also very death due enrolled option met be grateful the prior U.S., gpNMB a gpNMB, able and in patients pleased which care or experience. by read and of patients to our aggressive were physician and so hopeful there Australia. survival and is as the PFS, form patients
in be conducted recall X.X months. may PFS Phase duration is which in of reached also capecitabine, event will prior to similar was XXXrd safety METRIC. for lock data to X.X important triple cancer. You cleaning in endpoint. including powered response X.XX patient progression survival, point cancer PFS rate, study has the subset XX% success, is assessing no and stage breast and with for patients to the PFS known of From a The reduced benefit. The months that perspective Xeloda, expression, METRIC shown glemba positioned generic was gpNMB the for particularly patient of or points study valuation end METRIC primary equal these on ongoing secondary expressing less high breast and immerse months required in of has studies negative to with than population, reported at been a glemba in the gpNMB X.X our We statistical totality comparative and which of by later a PFS data well the The is name analysis. for select ratio that of and been clinical of in is data of the detect the X do to correlate survival populations end hazard a for filing believe study the preparation which has overall response
data remain The point we of primary the in line this report the track a As end EU. potential XXXX. in U.S. study study our to is on in we METRIC reaffirmed from and both filings the with quarter METRIC registration successful second afternoon, top
be seek submissions be a submission input will plan plans the authorities process. timelines. their commercial fully and health and supported next companion as the a validated to manufacturing to on feedback from by and and our prioritizing finding steps diagnostic important These we will Importantly, associated
that to considerably a hand. in manufacturing work of more previous have have made estimated we begin of an and an incremental these discussed, the spend million more ADC involved to approximately As of expensive in we we for stage is costly antibody most typical and commercial the at $XX areas, data after decision
of we seek to our timeline our pipeline is most advance complete the overall. regulatory our submissions, extend prudent as this believe will stuff this funds we to While use the
Biological positive with Application License to FDA the we the Assuming BLA half submitting data, in strategy XXXX. support or a plan regulatory of a that work on second will
As geographies on multiple we the bringing a remain we help who opportunity manufacturing glemba us. and across and on could have and indications past, in we believe the partner for we’ve open to the staged diagnostics the possibility stated supports maximize outlined of the approach
completed have of We a to work. steps number this support important
substance with chain, these antibody the quickly Qualification manufacturing execution. We had positive our have Each a the or move steps intermediate, manufacturing antibody Process we line and and supply product will established the the at Performance drug drug support We of manufactures BLA. with data PPQ commercial a of to with planning PPQ scale. portion forward antibody require top monoclonal will commercial slots manufacturing identified and commercial
We closely partner a based partner FDA current glemba. with from support to discuss diagnostic the with additional the BLA for submission submission work transition needed commercial our continue the diagnostic test lab test on with in to line meet and a to to by activates diagnostic preferred and PMA plant a
study, checkpoint market the evidence We single-agent Again, glemba gpNMB hopeful and a the and about of action, targeted glemba continue leader, its at we rate question a data X.X is of glemba. saw point and ASCO mature XX% based differentiated melanoma patients, METRIC study of that activity failed X product therapies. that or evaluated at a families in months offer MEK presented update will with check robust Celldex overall to arm also We mechanism III the option patient unresectable and state Phase the the previous believe and from and refractory feedback a our being givers melanoma. compelling stage on key unique glemba’s will an XXXX, disease. with look multi-cohort IV potential we stage support a to-date in heavily-pretreated clinical where for in Board Behind forward in Physician in response metastatic BRAF patients care next target in including to PFS opinion or who of Advisory new immunotherapy a
out shrinkage to number with very patients XX% in patients the Importantly, us these was a than the plot of waterfall close this experienced what responses. study of tumor where stood resist more to the coming
we checkpoint formal including Our combination into this is the arms To Varlilumab, the which a our we CDX-XXX, our overall very these of robustness with added tip goal data. if can end, cohorts of with we have completed patients. the and are combination increasing CDXX currently which number inhibitors patients recently conducting see agonist, enrolment gross responses, in XXXX is assets to factor data which enrolling cells in reported dendritic
As data forward to look determine to this emerges, position a next you. steps will sharing and with be we
renal with in XXX that BMS. to X we portion all combination across study of we patients Opdivo conducting in total, in across are study collaboration cohorts cell varli enrolled month with Phase planned glioblastoma. ovarian the glioblastoma, five colorectal January enrolment overall the Moving rate, this as completed in cohorts in X Phase In the carcinoma, cohorts’ of for of varli, of where objective cell squamous cancer, carcinoma XX survival. and cancer, rate objective and response the The is Phase head objective X the except primary primary neck
schedules include tumors Working we a XXXX their various dose meetings cohort each with of Secondary plan report in objectives BMS beginning profiling new and summer. to at this varli. from and evaluating medical data alternative of and patients
papillary study. with initially separate followed Phase also X our response. up with enrolled enrollment activity by the a malignancy where patients, patients include trail in a targets cell ovarian that carcinomas, our cell portion In to each the anti-tumor and on patients assess CDX-XXX, expanded we across to cell three XX clear tolerated renal preliminary January to cohorts measuring enrolments cohorts TIM-X carcinomas. TIM-X, maximum Moving overall clear expression The ADC by continuing escalation as is does includes the dose determine This study of dose, up-regulated. to is escalation dosing also
new as of into advance candidates XXXX Finally, close out our studies. we we pipeline two
therapies. Phase to many the of resistance apart breast, a of in in head well proposed an opened is in we design in ligand-independent and XX as previous a ability ligand-dependent carcinoma. as enrolment prognosis. with This gastric binding limited with We is open resistance, primary expressed believe the to the human head development This cell important thyroid, block the anti-PD-LX growth block ErbBX observe second combination XX in an mechanism Patients the checkpoint to approximately neck sets with treated receptor of of employs to To class survival, from and head which an it including particularly cell drugs and unique a as rate. regulating with to two Erbitux and cancers, action one targeted patients must study and and objective its signaling both to HPV X CDX-XXXX with objective squamous negative Simon combination of inhibitor, cancers antibody as epitope. and the squamous carcinoma. X is study that CDX-XXXX response advanced Erbitux is poor neck other CDX-XXXX and and been to objective trail activity response believed Erbitux in population neck, lung well First, advance designed a cell have due It much and melanoma. a stage is ErbBX, patients. monoclonal in cancer study Phase we a study the first stage options label
activity shown We associated Phase antibody linking is T activation agonist observed clinical agonist dendritic immune CDXX is expressed CDXX synergy cell a X interaction, cells. macrophages found with also of This cells B controlled results allowing antibodies. toxicity human consistent ligand have FC systemic is CDXX, The does targeted Also on CD a study of relative and many that through CDXX immune strong initiated other however, believe Potent also more on not activated activity with We the nodes may early CDX-XXXX cells XXXX potentiate studies; tumors. lymph response antibodies cancer and key agonist receptor to properties in the which unique has and in broad and their fully cells, encouraging limited cross activator we agonist that CDX-XXXX. dosing. require activation. has to near
the phase. our doses in up a to has while patients profile escalation dose X further to study expansion to advanced activation enroll during metastatic with potent CDX-XXXX subsequent a tolerated a in approximately dose desire the good Phase Finally, and determine studies. cancers, or expected demonstrated study This for preclinical XXX which recurrent is locally to safety phase recommend maximum remarkably immune
types. X.X evolved of completed Behind This mg/kg, nicely selected During the CDX-XXXX doses enter to we effects for X.XX XXXX. ranging phase We program. tumor IND four specific dose programs weeks or patients evaluate intolerance. to in will receive we and initiate clinic at has from KIT levels year. advance our be is manufacturing will and The anticipate CDX-XXXX in program to every dose expansion designed and disease of progression the year phase, combination and later mg/kg these this think escalation position tolerability once further good biological anti continue to cohorts efforts in are we CDX-XXXX the enabling will this until
We call broad a on diseases also the applications outline comprised and open we the AXL advance program. potentially then and and the are specific will antibody targets TAM XXXX questions. has continue up growing inflammation of to that, for will I which infectious Sam. MerTK, to Sam and program and by minestrones in oncology, With report ask the for financials TyroX,
